Position of the Transparency Council – Cablivi (caplacizumab)

At its meeting on 22 July 2024, the Transparency Council adopted position No. 76/2024 on the evaluation of the drug Cablivi (caplacizumab) under the drug program: “Treatment of patients with immune thrombotic thrombocytopenic purpura (ICD-10: M31.1)”.

Publication of the position >>